Silexion reports new preclinical immune data for SIL204 in KRAS cancers

Submitted by Anonymous on

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced new preclinical findings showing that its drug candidate SIL204 produced statistically significant changes in immune-related gene expression across human KRAS-mutant cancer... Silexion Therapeutics Corp. (NASDAQ: SLXN) announced new preclinical findings showing that its drug...

Serum cytokine profiles in a real-world cohort of KRAS-Mutant NSCLC and its therapeutic implications for subtype-specific immunotherapy

Submitted by Anonymous on

AbstractBackground KRAS‑mutant non‑small cell lung cancer (NSCLC) is heterogeneous, but the subtype‑specific profiles of systemic cytokines and their impact on immunotherapy outcomes remain unclear. Methods This retrospective study included 139 patients with KRAS‑mutant NSCLC stratified into G12C (44.6%), G12D (21.6%),...

Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation

Submitted by Anonymous on

Abstract Non-small cell lung cancer (NSCLC) with KRASG12C mutation is associated with poor prognosis and resistance to standard therapies. Sotorasib, a KRASG12C tyrosine kinase inhibitor, has shown clinical efficacy, yet its interaction with different irradiation modalities remains unclear. This study...

Real-world treatment pattern and clinical outcomes in Chinese NSCLC patients with KRAS G12C mutation

Submitted by Anonymous on

AbstractBackground To establish a historical benchmark by describing the treatment patterns and clinical outcomes of Chinese patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) in the real world, prior to the widespread availability of KRAS G12C inhibitors. Methods...

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation

Submitted by Anonymous on

InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today NANJING, China, July 9, 2026 /PRNewswire/ - InxMed Co., Ltd (“InxMed”), a clinical-stage biotechnology company dedicated to developing innovative therapies...

Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape

Submitted by Anonymous on

Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape Thematic Newsreels Advertisement Benjamin P. Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, reviews currently available therapies for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), noting...

Benjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies

Submitted by Anonymous on

Benjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies Thematic Newsreels Advertisement Benjamin P. Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, discusses research into moving KRAS G12C inhibitors from the second to...

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC

Submitted by Anonymous on

Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC / cancer, Huaqiu Shi, Liming Zhu, Ling Zhang, Lung cancer, NSCLC, Stephen Liu/X Stephen Liu: High Response Rates for Frontline Ifebemtinib/Garsorasib in KRAS G12C NSCLC Stephen Liu, Director...

Subscribe to Newsfeed